Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1Chondrosarcoma 1

Interventions

Cisplatin 44Paclitaxel 21Radiotherapy 20Brachytherapy 19Carboplatin 18Bevacizumab 7Drug Therapy 6camrelizumab 5toripalimab 4nimotuzumab 4Radiation 4Neoadjuvant Therapy 4Gemcitabine 4tislelizumab 3sintilimab 3pembrolizumab 3apatinib 3Vaccines 3TP protocol 3Surgical Procedures, Operative 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3nedaplatin 2fludarabine 2endostar protein 2anlotinib 2Topotecan 2Surveys and Questionnaires 2Sentinel Lymph Node Biopsy 2Radiotherapy, Intensity-Modulated 2Mindfulness 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Uterine Cervical Neoplasms × TQ-B3525 × Clear all
NCT04836663 2021-06-01

A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
90 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡